Search results
The Zacks Analyst Blog Highlights Gilead Sciences, GSK, Deciphera, Bristol Myers and Editas Medicine
Zacks via Yahoo Finance· 10 hours agoThe upside can be attributed to rising HIV and vaccine product sales, partially offset by the...
Russell Investments Group Ltd. Trims Stock Holdings in Ingersoll Rand Inc. (NYSE:IR)
ETF DAILY NEWS· 1 day agoRussell Investments Group Ltd. lowered its stake in shares of Ingersoll Rand Inc. (NYSE:IR – Free...
...Phase III Randomized, Double-Masked Vehicle Controlled VELOS-4 Trial Evaluating Tanfanercept for ...
NBC 17 Raleigh· 8 hours agoHanAll has initiated a Phase III VELOS-4 study to evaluate the efficacy and safety of tanfanercept in dry eye based on the findings from the previous Phase III VELOS-3 study. Tanfanercept demonstrated ...
Amgen Inc (AMGN) Q1 2024 Earnings: Aligns with EPS Projections A
Guru Focus· 1 day agoRevenue: $7.4 billion, up 22% year-over-year, surpassing estimates of $7.435 billion.Net Income: Reported a net loss of $113 million, a significant drop from a
License of 14 Patanjali products cancelled, criminal complaint filed against Ramdev, Balkrishna,...
Investing.com· 5 days agoLicense of 14 Patanjali products cancelled, criminal complaint filed against Ramdev, Balkrishna,...
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 1 day agoGEORGE TOWN, Cayman Islands, May 02, 2024 (GLOBE NEWSWIRE) -- Consolidated Water Co. Ltd. (NASDAQ Global Select Market: CWCO), a leading developer and operator of advanced ...
Inspira Technologies begins production of ART100 device By Investing.com
Investing.com· 1 day agoRA'ANANA, Israel - Inspira Technologies OXY B.H.N. Ltd. (NASDAQ:IINN, IINNW), a medical technology...
SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business...
Benzinga· 1 day ago– Achieved $21.0 million in OGSIVEO® (nirogacestat) net product revenue in the first quarter – – Received validation from the EMA for MAA of nirogacestat for the treatment of adults with desmoid tumors – –
AMGEN REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS
Fairfield-Suisun Daily Republic· 23 hours agoAmgen (NASDAQ:AMGN) today announced financial results for the first quarter 2024. "With many of our innovative products delivering strong growth and promising new medicines ...
Waterproofing Membrane Market Set to Surpass USD 60.48 Billion by 2030, Fueled by Growing...
Digital Journal· 4 hours agoThe waterproofing membrane market is poised for substantial growth, driven by escalating demands...
